secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001493152-24-020964
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics appoints Dr. William Peacock as Chief Clinical Officer for Phase II concussion trial
--------------------------------------------------------------------------------

- Appointed Dr. William 'Frank' Peacock as Chief Clinical Officer effective May 22, 2024.
- Dr. Peacock will oversee upcoming Phase II trial of ONP-002 for concussion in emergency departments.
- Dr. Peacock is Vice Chair for Emergency Medicine Research at Baylor College of Medicine.
- ONP-002, a new chemical entity delivered intranasally, showed safety in Phase I; Phase II planned.
- Concussion is an unmet need with ~69M cases annually; post-concussion syndrome occurs in up to 20% of patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224020964/0001493152-24-020964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224020964/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer